drugset / Trial / NCT03487939

Neoadjuvant FOLFOXIRI Chemotherapy in Resectable Liver Metastasis of Colorectal Cancer

NCT03487939

Phase 2 Unknown 30 enrolled China Medical University, China
NaSingle-groupOpen-labelTreatment

Summary

To evaluate the efficacy and safety of neoadjuvant FOLFOXIRI chemotherapy (irinotecan, oxaliplatin and fluorouracil) in the patients with resectable liver metastasis of colorectal cancer

Timeline

Start
2018-05-01
Primary completion
2021-10-01
Completion
2021-10-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Irinotecan Small molecule 150 mg/m2 Intravenous
Subject Levoleucovorin Unknown 200 mg/m2 Intravenous
Subject Oxaliplatin Small molecule 85 mg/m2 Intravenous
Subject fluorouracil Small molecule 2800 mg/m2 Intravenous

Indications